Global Vendor Neutral Archive (VNA) & PACS Market: By Modality, By Deployment, By Product Type, By Vendor Type, By Application, By End-User, By Region & Segmental Insights Trends and Forecast, 2024 – 2034

  • Industry: Healthcare
  • Report ID: TNR-110-1087
  • Number of Pages: 420
  • Table/Charts : Yes
  • May, 2024
  • Base Year : 2024
  • No. of Companies : 10+
  • No. of Countries : 29
  • Views : 10120
  • Covid Impact Covered: Yes
  • War Impact Covered: Yes
  • Formats : PDF, Excel, PPT

Vendor Neutral Archive (VNA) and Picture Archiving and Communication System (PACS) are both integral components of medical imaging informatics, playing crucial roles in managing, storing, and accessing medical images and associated patient data within healthcare organizations. PACS primarily focuses on the acquisition, storage, retrieval, distribution, and display of medical images generated from various imaging modalities, such as X-ray, MRI, CT scans, ultrasound, and more. It is typically used within radiology departments for diagnostic interpretation and clinical decision-making.

VNA, on the other hand, is designed to serve as a central repository for storing and managing medical images and related data from multiple imaging modalities and departments across the entire healthcare enterprise. It aims to address issues of data silos, interoperability, and long-term data retention, offering a vendor-agnostic platform for archiving images and ensuring data accessibility and integrity. Integration of AI algorithms and advanced analytics capabilities into VNA and PACS platforms is enhancing diagnostic capabilities, clinical decision-making, and workflow efficiency. AI-powered tools for image analysis, interpretation, and triaging are being integrated with VNA and PACS solutions to automate routine tasks, accelerate image processing, and improve diagnostic accuracy and efficiency.

In terms of revenue, the global vendor neutral archive (VNA) & PACS market was worth US$ 4.4 Bn in 2023, anticipated to witness CAGR of 9.8% during 2024 – 2034.

Global Vendor Neutral Archive (VNA) & PACS Market Revenue & Forecast, (US$ Million), 2016 – 2034

Global Vendor Neutral Archive VNA PACS Market Trends and Insights

Growing Volume and Complexity of Medical Imaging Data: The proliferation of medical imaging modalities, such as MRI, CT, ultrasound, and digital radiography, has led to a significant increase in the volume and complexity of medical imaging data. VNA and PACS solutions are equipped to handle large datasets and diverse image formats while ensuring efficient storage, retrieval, and management of medical images, diagnostic reports, and associated patient information.

Increasing Adoption of Enterprise Imaging Solutions: Healthcare organizations are increasingly adopting enterprise imaging strategies to consolidate and manage medical imaging data from multiple departments, modalities, and locations. VNA and PACS solutions play a crucial role in these strategies by providing a centralized repository for storing, accessing, and sharing medical images and associated patient data across the enterprise.

Advancements in Cloud-based Imaging Solutions: Cloud-based VNA and PACS solutions are gaining traction due to their scalability, flexibility, and cost-effectiveness. Cloud deployment offers healthcare providers the ability to store and access medical imaging data securely, offload IT infrastructure management, and support remote access and collaboration. Additionally, cloud-based VNA and PACS solutions enable seamless integration with other cloud-based healthcare applications and services.

Vendor Neutral Archive VNA has Garnered Major Market Share in the Global Vendor Neutral Archive VNAPACS Market in 2023

The demand for Vendor Neutral Archive (VNA) solutions is primarily driven by several factors that contribute to the efficient management, storage, and accessibility of medical imaging data across healthcare organizations. Healthcare institutions often accumulate vast amounts of medical imaging data from multiple modalities, departments, and facilities. VNA solutions enable the consolidation of diverse image formats and data sources into a centralized repository, promoting interoperability and seamless access to patient information across the enterprise. With the exponential growth of medical imaging data, healthcare providers require scalable storage solutions capable of accommodating large datasets while optimizing storage utilization. VNA platforms offer scalable storage architectures and advanced data compression techniques to manage growing volumes of images efficiently.

By Application Cardiology and Radiology Segment had the Highest Share in the Global Vendor Neutral Archive (VNA) & PACS Market in 2023.

Cardiology and Radiology segment dominated the global Vendor Neutral Archive VNA PACS market, in terms of revenue and is estimated to sustain its dominance over the forecast period. Cardiologists require high-quality imaging studies to accurately diagnose various cardiac conditions, assess cardiac function, and plan appropriate treatment strategies. VNA & PACS solutions support interventional cardiology procedures by providing access to pre-procedural imaging studies, guiding catheter-based interventions, and facilitating post-procedure assessment. Radiology is one of the largest users of medical imaging technology, encompassing various modalities such as X-ray, MRI, CT, ultrasound, and nuclear medicine. Radiologists rely on advanced visualization tools, diagnostic workstations, and decision support systems integrated into PACS for image interpretation and diagnosis.

By End User Hospitals & Clinics had the Highest Share in the Global Vendor Neutral Archive (VNA) & PACS Market in 2023.

Hospitals and clinics are increasingly transitioning from traditional film-based radiology systems to digital imaging solutions. VNA & PACS enable healthcare facilities to digitize, store, and manage medical images in electronic format, facilitating seamless integration with electronic health records (EHR) and other clinical systems. The volume of medical imaging data generated by hospitals and clinics continues to grow rapidly, driven by factors such as technological advancements in imaging modalities and increasing patient volumes.

VNA & PACS solutions offer scalable, centralized storage and efficient image management capabilities, allowing healthcare providers to store, retrieve, and share large volumes of medical images across the organization. VNA & PACS solutions streamline clinical workflows within hospitals and clinics by providing radiologists and clinicians with instant access to patient imaging studies and related information. This enables faster diagnosis, treatment planning, and decision-making, leading to improved patient outcomes and satisfaction.

North America has garnered major market share in the vendor neutral archive (VNA) & PACS market in 2023.

Healthcare facilities in North America are subject to stringent regulatory requirements regarding the storage, management, and security of patient health information, including medical images. VNA & PACS solutions help healthcare providers comply with regulations such as the Health Insurance Portability and Accountability Act (HIPAA) by providing secure, auditable storage and access controls for medical images. With the increasing complexity of healthcare delivery systems and the growing importance of care coordination, there is a strong demand for interoperable IT solutions that enable seamless data exchange across different healthcare settings and systems. VNA & PACS solutions facilitate interoperability by standardizing image formats, protocols, and interfaces, allowing healthcare organizations to share and access medical images from disparate sources and systems.

Competitive Landscape: Global Vendor Neutral Archive (VNA) & PACS Market:

  • Agfa Healthcare NV
  • Dell Technologies Inc.
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • IBM Corporation
  • Koninklijke Philips NV
  • Lexmark International Inc.
  • McKesson Corporation
  • Novarad Corporation
  • Siemens Healthineers AG
  • Other Industry Participants

Global Vendor Neutral Archive (VNA) & PACS Market: Key Takeaways 

Report Specifications Details
Market Revenue in 2023 US$ 4.4 Bn
Market Size Forecast by 2034 US$ 9.1 Bn
Growth Rate (CAGR) 9.8%
Historic Data 2016 – 2022
Base Year for Estimation 2023
Forecast Period 2024 – 2034
Report Inclusions Market Size & Estimates, Market Dynamics, Competitive Scenario, Trends, Growth Factors, Market Determinants, Key Investment Segmentation, Product/Service/Solutions Benchmarking
Segments Covered By Modality, By Deployment, By Product Type, By Vendor Type, By Application, By End-User
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Countries Covered U.S., Canada, Mexico, Rest of North America,  France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe,  China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific,  Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,  Brazil, Argentina, Rest of Latin America
Key Players Agfa Healthcare NV,Dell Technologies Inc.,FUJIFILM Holdings Corporation,GE Healthcare,IBM Corporation,Koninklijke Philips NV,Lexmark International Inc.,McKesson Corporation,Novarad Corporation,Siemens Healthineers AG, Other Market Participants
Customization Scope Customization allows for the inclusion/modification of content pertaining to geographical regions, countries, and specific market segments.
Pricing & Procurement Options Explore purchase options tailored to your specific research requirements
Contact Details Consult With Our Expert

Japan (Toll-Free):  +81 663-386-8111

South Korea (Toll-Free):  +82-808- 703-126

Saudi Arabia (Toll-Free):  +966 800-850-1643

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

E-mail:  askanexpert@thenicheresearch.com

Global Vendor Neutral Archive (VNA) & PACS Market Scope: 

By Modality

  • CT
  • Mammography
  • MRI
  • Ultrasound
  • X-Rays
  • PET

By Deployment

  • On-Premise
  • Cloud-Based
  • Hybrid Model

By Product Type

  • VNA
    • Department VNA
    • Multi-Department VNA
    • Multi-Site VNA
  • PACS
    • Department PACS
    • Multi-Department PACS
    • Multi-Site PACS

By Vendor Type

  • Independent Vendor
  • Third-party Vendor

By Application

  • Cardiology
  • Orthopedic
  • Oncology
  • Neurology
  • Obstetrics and Gynecology
  • Others

By End User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

Report Layout

Table of Contents

.

1.Market Scope
1.1.Market Segmentation
1.2.Years Considered
1.2.1.Historic Years: 2016 – 2022
1.2.2.Base Year: 2023
1.2.3.Forecast Years: 2024 – 2034
2.Key Target Audiences
3.Research Methodology
3.1.Primary Research
3.1.1.Research Questionnaire
3.1.2.Global Percentage Breakdown
3.1.3.Primary Interviews: Key Opinion Leaders (KOLs)
3.2.Secondary Research
3.2.1.Paid Databases
3.2.2.Secondary Sources
3.3.Market Size Estimates
3.3.1.Top-Down Approach
3.3.2.Bottom-Up Approach
3.4.Data Triangulation Methodology
3.5.Research Assumptions
4.Recommendations and Insights from TNR’s Perspective**
5.Holistic Overview of Vendor Neutral Archive (VNA) and PACS Market
6.Market Synopsis: Vendor Neutral Archive (VNA) and PACS Market
7.Vendor Neutral Archive (VNA) and PACS Market Analysis: Qualitative Perspective
7.1.Introduction
7.1.1.Product Definition
7.1.2.Industry Development
7.2.Market Dynamics
7.2.1.Drivers
7.2.2.Restraints
7.2.3.Opportunities
7.2.4.Challenges
7.3.Trends in Vendor Neutral Archive (VNA) and PACS Market
7.4.Market Determinants Radar Chart
7.5.Macro-Economic and Micro-Economic Indicators: Vendor Neutral Archive (VNA) and PACS Market
7.6.Porter’s Five Force Analysis
7.7.Impact of Covid-19 on Vendor Neutral Archive (VNA) and PACS Market
8.Global Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
8.1.Overview
8.1.1.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn)
8.2.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
8.2.1.CT
8.2.1.1.Definition
8.2.1.2.Market Estimation and Penetration, 2016 – 2023
8.2.1.3.Market Forecast, 2024 – 2034
8.2.1.4.Compound Annual Growth Rate (CAGR)
8.2.1.5.Regional Bifurcation
8.2.1.5.1.North America
8.2.1.5.1.1.Market Estimation, 2016 – 2023
8.2.1.5.1.2.Market Forecast, 2024 – 2034
8.2.1.5.2.Europe
8.2.1.5.2.1.Market Estimation, 2016 – 2023
8.2.1.5.2.2.Market Forecast, 2024 – 2034
8.2.1.5.3.Asia Pacific
8.2.1.5.3.1.Market Estimation, 2016 – 2023
8.2.1.5.3.2.Market Forecast, 2024 – 2034
8.2.1.5.4.Middle East and Africa
8.2.1.5.4.1.Market Estimation, 2016 – 2023
8.2.1.5.4.2.Market Forecast, 2024 – 2034
8.2.1.5.5.Latin America
8.2.1.5.5.1.Market Estimation, 2016 – 2023
8.2.1.5.5.2.Market Forecast, 2024 – 2034
8.2.2.Mammography
8.2.2.1.Definition
8.2.2.2.Market Estimation and Penetration, 2016 – 2023
8.2.2.3.Market Forecast, 2024 – 2034
8.2.2.4.Compound Annual Growth Rate (CAGR)
8.2.2.5.Regional Bifurcation
8.2.2.5.1.North America
8.2.2.5.1.1.Market Estimation, 2016 – 2023
8.2.2.5.1.2.Market Forecast, 2024 – 2034
8.2.2.5.2.Europe
8.2.2.5.2.1.Market Estimation, 2016 – 2023
8.2.2.5.2.2.Market Forecast, 2024 – 2034
8.2.2.5.3.Asia Pacific
8.2.2.5.3.1.Market Estimation, 2016 – 2023
8.2.2.5.3.2.Market Forecast, 2024 – 2034
8.2.2.5.4.Middle East and Africa
8.2.2.5.4.1.Market Estimation, 2016 – 2023
8.2.2.5.4.2.Market Forecast, 2024 – 2034
8.2.2.5.5.Latin America
8.2.2.5.5.1.Market Estimation, 2016 – 2023
8.2.2.5.5.2.Market Forecast, 2024 – 2034
8.2.3.MRI
8.2.3.1.Definition
8.2.3.2.Market Estimation and Penetration, 2016 – 2023
8.2.3.3.Market Forecast, 2024 – 2034
8.2.3.4.Compound Annual Growth Rate (CAGR)
8.2.3.5.Regional Bifurcation
8.2.3.5.1.North America
8.2.3.5.1.1.Market Estimation, 2016 – 2023
8.2.3.5.1.2.Market Forecast, 2024 – 2034
8.2.3.5.2.Europe
8.2.3.5.2.1.Market Estimation, 2016 – 2023
8.2.3.5.2.2.Market Forecast, 2024 – 2034
8.2.3.5.3.Asia Pacific
8.2.3.5.3.1.Market Estimation, 2016 – 2023
8.2.3.5.3.2.Market Forecast, 2024 – 2034
8.2.3.5.4.Middle East and Africa
8.2.3.5.4.1.Market Estimation, 2016 – 2023
8.2.3.5.4.2.Market Forecast, 2024 – 2034
8.2.3.5.5.Latin America
8.2.3.5.5.1.Market Estimation, 2016 – 2023
8.2.3.5.5.2.Market Forecast, 2024 – 2034
8.2.4.Ultrasound
8.2.4.1.Definition
8.2.4.2.Market Estimation and Penetration, 2016 – 2023
8.2.4.3.Market Forecast, 2024 – 2034
8.2.4.4.Compound Annual Growth Rate (CAGR)
8.2.4.5.Regional Bifurcation
8.2.4.5.1.North America
8.2.4.5.1.1.Market Estimation, 2016 – 2023
8.2.4.5.1.2.Market Forecast, 2024 – 2034
8.2.4.5.2.Europe
8.2.4.5.2.1.Market Estimation, 2016 – 2023
8.2.4.5.2.2.Market Forecast, 2024 – 2034
8.2.4.5.3.Asia Pacific
8.2.4.5.3.1.Market Estimation, 2016 – 2023
8.2.4.5.3.2.Market Forecast, 2024 – 2034
8.2.4.5.4.Middle East and Africa
8.2.4.5.4.1.Market Estimation, 2016 – 2023
8.2.4.5.4.2.Market Forecast, 2024 – 2034
8.2.4.5.5.Latin America
8.2.4.5.5.1.Market Estimation, 2016 – 2023
8.2.4.5.5.2.Market Forecast, 2024 – 2034
8.2.5.X-Rays
8.2.5.1.Definition
8.2.5.2.Market Estimation and Penetration, 2016 – 2023
8.2.5.3.Market Forecast, 2024 – 2034
8.2.5.4.Compound Annual Growth Rate (CAGR)
8.2.5.5.Regional Bifurcation
8.2.5.5.1.North America
8.2.5.5.1.1.Market Estimation, 2016 – 2023
8.2.5.5.1.2.Market Forecast, 2024 – 2034
8.2.5.5.2.Europe
8.2.5.5.2.1.Market Estimation, 2016 – 2023
8.2.5.5.2.2.Market Forecast, 2024 – 2034
8.2.5.5.3.Asia Pacific
8.2.5.5.3.1.Market Estimation, 2016 – 2023
8.2.5.5.3.2.Market Forecast, 2024 – 2034
8.2.5.5.4.Middle East and Africa
8.2.5.5.4.1.Market Estimation, 2016 – 2023
8.2.5.5.4.2.Market Forecast, 2024 – 2034
8.2.5.5.5.Latin America
8.2.5.5.5.1.Market Estimation, 2016 – 2023
8.2.5.5.5.2.Market Forecast, 2024 – 2034
8.2.6.PET
8.2.6.1.Definition
8.2.6.2.Market Estimation and Penetration, 2016 – 2023
8.2.6.3.Market Forecast, 2024 – 2034
8.2.6.4.Compound Annual Growth Rate (CAGR)
8.2.6.5.Regional Bifurcation
8.2.6.5.1.North America
8.2.6.5.1.1.Market Estimation, 2016 – 2023
8.2.6.5.1.2.Market Forecast, 2024 – 2034
8.2.6.5.2.Europe
8.2.6.5.2.1.Market Estimation, 2016 – 2023
8.2.6.5.2.2.Market Forecast, 2024 – 2034
8.2.6.5.3.Asia Pacific
8.2.6.5.3.1.Market Estimation, 2016 – 2023
8.2.6.5.3.2.Market Forecast, 2024 – 2034
8.2.6.5.4.Middle East and Africa
8.2.6.5.4.1.Market Estimation, 2016 – 2023
8.2.6.5.4.2.Market Forecast, 2024 – 2034
8.2.6.5.5.Latin America
8.2.6.5.5.1.Market Estimation, 2016 – 2023
8.2.6.5.5.2.Market Forecast, 2024 – 2034
8.3.Key Segment for Channeling Investments
8.3.1.By Modality
9.Global Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
9.1.Overview
9.2.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
9.2.1.Cloud
9.2.1.1.Definition
9.2.1.2.Market Estimation and Penetration, 2016 – 2023
9.2.1.3.Market Forecast, 2024 – 2034
9.2.1.4.Compound Annual Growth Rate (CAGR)
9.2.1.5.Regional Bifurcation
9.2.1.5.1.North America
9.2.1.5.1.1.Market Estimation, 2016 – 2023
9.2.1.5.1.2.Market Forecast, 2024 – 2034
9.2.1.5.2.Europe
9.2.1.5.2.1.Market Estimation, 2016 – 2023
9.2.1.5.2.2.Market Forecast, 2024 – 2034
9.2.1.5.3.Asia Pacific
9.2.1.5.3.1.Market Estimation, 2016 – 2023
9.2.1.5.3.2.Market Forecast, 2024 – 2034
9.2.1.5.4.Middle East and Africa
9.2.1.5.4.1.Market Estimation, 2016 – 2023
9.2.1.5.4.2.Market Forecast, 2024 – 2034
9.2.1.5.5.Latin America
9.2.1.5.5.1.Market Estimation, 2016 – 2023
9.2.1.5.5.2.Market Forecast, 2024 – 2034
9.2.2.On-Premises
9.2.2.1.Definition
9.2.2.2.Market Estimation and Penetration, 2016 – 2023
9.2.2.3.Market Forecast, 2024 – 2034
9.2.2.4.Compound Annual Growth Rate (CAGR)
9.2.2.5.Regional Bifurcation
9.2.2.5.1.North America
9.2.2.5.1.1.Market Estimation, 2016 – 2023
9.2.2.5.1.2.Market Forecast, 2024 – 2034
9.2.2.5.2.Europe
9.2.2.5.2.1.Market Estimation, 2016 – 2023
9.2.2.5.2.2.Market Forecast, 2024 – 2034
9.2.2.5.3.Asia Pacific
9.2.2.5.3.1.Market Estimation, 2016 – 2023
9.2.2.5.3.2.Market Forecast, 2024 – 2034
9.2.2.5.4.Middle East and Africa
9.2.2.5.4.1.Market Estimation, 2016 – 2023
9.2.2.5.4.2.Market Forecast, 2024 – 2034
9.2.2.5.5.Latin America
9.2.2.5.5.1.Market Estimation, 2016 – 2023
9.2.2.5.5.2.Market Forecast, 2024 – 2034
9.2.3.Hybrid
9.2.3.1.Definition
9.2.3.2.Market Estimation and Penetration, 2016 – 2023
9.2.3.3.Market Forecast, 2024 – 2034
9.2.3.4.Compound Annual Growth Rate (CAGR)
9.2.3.5.Regional Bifurcation
9.2.3.5.1.North America
9.2.3.5.1.1.Market Estimation, 2016 – 2023
9.2.3.5.1.2.Market Forecast, 2024 – 2034
9.2.3.5.2.Europe
9.2.3.5.2.1.Market Estimation, 2016 – 2023
9.2.3.5.2.2.Market Forecast, 2024 – 2034
9.2.3.5.3.Asia Pacific
9.2.3.5.3.1.Market Estimation, 2016 – 2023
9.2.3.5.3.2.Market Forecast, 2024 – 2034
9.2.3.5.4.Middle East and Africa
9.2.3.5.4.1.Market Estimation, 2016 – 2023
9.2.3.5.4.2.Market Forecast, 2024 – 2034
9.2.3.5.5.Latin America
9.2.3.5.5.1.Market Estimation, 2016 – 2023
9.2.3.5.5.2.Market Forecast, 2024 – 2034
9.3.Key Segment for Channeling Investments
9.3.1.By Deployment
10.Global Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
10.1.Overview
10.2.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
10.2.1.VNA (Definition, Market Estimation and Penetration, 2016 – 2023, Market Estimation (2016 – 2023), Market Forecast (2024 – 2034), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Department VNA, Multi-Department VNA, Multi-Site VNA)
10.2.1.1.Department VNA
10.2.1.2.Multi-Department VNA
10.2.1.3.Multi-Site VNA
10.2.2.PACS (Definition, Market Estimation and Penetration, 2016 – 2023, Market Estimation (2016 – 2023), Market Forecast (2024 – 2034), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Department PACS, Multi-Department PACS, Multi-Site PACS)
10.2.2.1.Department PACS
10.2.2.2.Multi-Department PACS
10.2.2.3.Multi-Site PACS
10.3.Key Segment for Channeling Investments
10.3.1.By Product Type
11.Global Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
11.1.Overview
11.2.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
11.2.1.Independent Vendor
11.2.1.1.Definition
11.2.1.2.Market Estimation and Penetration, 2016 – 2023
11.2.1.3.Market Forecast, 2024 – 2034
11.2.1.4.Compound Annual Growth Rate (CAGR)
11.2.1.5.Regional Bifurcation
11.2.1.5.1.North America
11.2.1.5.1.1.Market Estimation, 2016 – 2023
11.2.1.5.1.2.Market Forecast, 2024 – 2034
11.2.1.5.2.Europe
11.2.1.5.2.1.Market Estimation, 2016 – 2023
11.2.1.5.2.2.Market Forecast, 2024 – 2034
11.2.1.5.3.Asia Pacific
11.2.1.5.3.1.Market Estimation, 2016 – 2023
11.2.1.5.3.2.Market Forecast, 2024 – 2034
11.2.1.5.4.Middle East and Africa
11.2.1.5.4.1.Market Estimation, 2016 – 2023
11.2.1.5.4.2.Market Forecast, 2024 – 2034
11.2.1.5.5.Latin America
11.2.1.5.5.1.Market Estimation, 2016 – 2023
11.2.1.5.5.2.Market Forecast, 2024 – 2034
11.2.2.Third-party Vendor
11.2.2.1.Definition
11.2.2.2.Market Estimation and Penetration, 2016 – 2023
11.2.2.3.Market Forecast, 2024 – 2034
11.2.2.4.Compound Annual Growth Rate (CAGR)
11.2.2.5.Regional Bifurcation
11.2.2.5.1.North America
11.2.2.5.1.1.Market Estimation, 2016 – 2023
11.2.2.5.1.2.Market Forecast, 2024 – 2034
11.2.2.5.2.Europe
11.2.2.5.2.1.Market Estimation, 2016 – 2023
11.2.2.5.2.2.Market Forecast, 2024 – 2034
11.2.2.5.3.Asia Pacific
11.2.2.5.3.1.Market Estimation, 2016 – 2023
11.2.2.5.3.2.Market Forecast, 2024 – 2034
11.2.2.5.4.Middle East and Africa
11.2.2.5.4.1.Market Estimation, 2016 – 2023
11.2.2.5.4.2.Market Forecast, 2024 – 2034
11.2.2.5.5.Latin America
11.2.2.5.5.1.Market Estimation, 2016 – 2023
11.2.2.5.5.2.Market Forecast, 2024 – 2034
11.3.Key Segment for Channeling Investments
11.3.1.By Vendor Type
12.Global Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
12.1.Overview
12.2.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
12.2.1.Cardiology
12.2.1.1.Definition
12.2.1.2.Market Estimation and Penetration, 2016 – 2023
12.2.1.3.Market Forecast, 2024 – 2034
12.2.1.4.Compound Annual Growth Rate (CAGR)
12.2.1.5.Regional Bifurcation
12.2.1.5.1.North America
12.2.1.5.1.1.Market Estimation, 2016 – 2023
12.2.1.5.1.2.Market Forecast, 2024 – 2034
12.2.1.5.2.Europe
12.2.1.5.2.1.Market Estimation, 2016 – 2023
12.2.1.5.2.2.Market Forecast, 2024 – 2034
12.2.1.5.3.Asia Pacific
12.2.1.5.3.1.Market Estimation, 2016 – 2023
12.2.1.5.3.2.Market Forecast, 2024 – 2034
12.2.1.5.4.Middle East and Africa
12.2.1.5.4.1.Market Estimation, 2016 – 2023
12.2.1.5.4.2.Market Forecast, 2024 – 2034
12.2.1.5.5.Latin America
12.2.1.5.5.1.Market Estimation, 2016 – 2023
12.2.1.5.5.2.Market Forecast, 2024 – 2034
12.2.2.Orthopedic
12.2.2.1.Definition
12.2.2.2.Market Estimation and Penetration, 2016 – 2023
12.2.2.3.Market Forecast, 2024 – 2034
12.2.2.4.Compound Annual Growth Rate (CAGR)
12.2.2.5.Regional Bifurcation
12.2.2.5.1.North America
12.2.2.5.1.1.Market Estimation, 2016 – 2023
12.2.2.5.1.2.Market Forecast, 2024 – 2034
12.2.2.5.2.Europe
12.2.2.5.2.1.Market Estimation, 2016 – 2023
12.2.2.5.2.2.Market Forecast, 2024 – 2034
12.2.2.5.3.Asia Pacific
12.2.2.5.3.1.Market Estimation, 2016 – 2023
12.2.2.5.3.2.Market Forecast, 2024 – 2034
12.2.2.5.4.Middle East and Africa
12.2.2.5.4.1.Market Estimation, 2016 – 2023
12.2.2.5.4.2.Market Forecast, 2024 – 2034
12.2.2.5.5.Latin America
12.2.2.5.5.1.Market Estimation, 2016 – 2023
12.2.2.5.5.2.Market Forecast, 2024 – 2034
12.2.3.Oncology
12.2.3.1.Definition
12.2.3.2.Market Estimation and Penetration, 2016 – 2023
12.2.3.3.Market Forecast, 2024 – 2034
12.2.3.4.Compound Annual Growth Rate (CAGR)
12.2.3.5.Regional Bifurcation
12.2.3.5.1.North America
12.2.3.5.1.1.Market Estimation, 2016 – 2023
12.2.3.5.1.2.Market Forecast, 2024 – 2034
12.2.3.5.2.Europe
12.2.3.5.2.1.Market Estimation, 2016 – 2023
12.2.3.5.2.2.Market Forecast, 2024 – 2034
12.2.3.5.3.Asia Pacific
12.2.3.5.3.1.Market Estimation, 2016 – 2023
12.2.3.5.3.2.Market Forecast, 2024 – 2034
12.2.3.5.4.Middle East and Africa
12.2.3.5.4.1.Market Estimation, 2016 – 2023
12.2.3.5.4.2.Market Forecast, 2024 – 2034
12.2.3.5.5.Latin America
12.2.3.5.5.1.Market Estimation, 2016 – 2023
12.2.3.5.5.2.Market Forecast, 2024 – 2034
12.2.4.Neurology
12.2.4.1.Definition
12.2.4.2.Market Estimation and Penetration, 2016 – 2023
12.2.4.3.Market Forecast, 2024 – 2034
12.2.4.4.Compound Annual Growth Rate (CAGR)
12.2.4.5.Regional Bifurcation
12.2.4.5.1.North America
12.2.4.5.1.1.Market Estimation, 2016 – 2023
12.2.4.5.1.2.Market Forecast, 2024 – 2034
12.2.4.5.2.Europe
12.2.4.5.2.1.Market Estimation, 2016 – 2023
12.2.4.5.2.2.Market Forecast, 2024 – 2034
12.2.4.5.3.Asia Pacific
12.2.4.5.3.1.Market Estimation, 2016 – 2023
12.2.4.5.3.2.Market Forecast, 2024 – 2034
12.2.4.5.4.Middle East and Africa
12.2.4.5.4.1.Market Estimation, 2016 – 2023
12.2.4.5.4.2.Market Forecast, 2024 – 2034
12.2.4.5.5.Latin America
12.2.4.5.5.1.Market Estimation, 2016 – 2023
12.2.4.5.5.2.Market Forecast, 2024 – 2034
12.2.5.Obstetrics and Gynecology
12.2.5.1.Definition
12.2.5.2.Market Estimation and Penetration, 2016 – 2023
12.2.5.3.Market Forecast, 2024 – 2034
12.2.5.4.Compound Annual Growth Rate (CAGR)
12.2.5.5.Regional Bifurcation
12.2.5.5.1.North America
12.2.5.5.1.1.Market Estimation, 2016 – 2023
12.2.5.5.1.2.Market Forecast, 2024 – 2034
12.2.5.5.2.Europe
12.2.5.5.2.1.Market Estimation, 2016 – 2023
12.2.5.5.2.2.Market Forecast, 2024 – 2034
12.2.5.5.3.Asia Pacific
12.2.5.5.3.1.Market Estimation, 2016 – 2023
12.2.5.5.3.2.Market Forecast, 2024 – 2034
12.2.5.5.4.Middle East and Africa
12.2.5.5.4.1.Market Estimation, 2016 – 2023
12.2.5.5.4.2.Market Forecast, 2024 – 2034
12.2.5.5.5.Latin America
12.2.5.5.5.1.Market Estimation, 2016 – 2023
12.2.5.5.5.2.Market Forecast, 2024 – 2034
12.2.6.Others
12.2.6.1.Definition
12.2.6.2.Market Estimation and Penetration, 2016 – 2023
12.2.6.3.Market Forecast, 2024 – 2034
12.2.6.4.Compound Annual Growth Rate (CAGR)
12.2.6.5.Regional Bifurcation
12.2.6.5.1.North America
12.2.6.5.1.1.Market Estimation, 2016 – 2023
12.2.6.5.1.2.Market Forecast, 2024 – 2034
12.2.6.5.2.Europe
12.2.6.5.2.1.Market Estimation, 2016 – 2023
12.2.6.5.2.2.Market Forecast, 2024 – 2034
12.2.6.5.3.Asia Pacific
12.2.6.5.3.1.Market Estimation, 2016 – 2023
12.2.6.5.3.2.Market Forecast, 2024 – 2034
12.2.6.5.4.Middle East and Africa
12.2.6.5.4.1.Market Estimation, 2016 – 2023
12.2.6.5.4.2.Market Forecast, 2024 – 2034
12.2.6.5.5.Latin America
12.2.6.5.5.1.Market Estimation, 2016 – 2023
12.2.6.5.5.2.Market Forecast, 2024 – 2034
12.3.Key Segment for Channeling Investments
12.3.1.By Application
13.Global Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
13.1.Overview
13.2.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
13.2.1.Hospitals and Clinics
13.2.1.1.Definition
13.2.1.2.Market Estimation and Penetration, 2016 – 2023
13.2.1.3.Market Forecast, 2024 – 2034
13.2.1.4.Compound Annual Growth Rate (CAGR)
13.2.1.5.Regional Bifurcation
13.2.1.5.1.North America
13.2.1.5.1.1.Market Estimation, 2016 – 2023
13.2.1.5.1.2.Market Forecast, 2024 – 2034
13.2.1.5.2.Europe
13.2.1.5.2.1.Market Estimation, 2016 – 2023
13.2.1.5.2.2.Market Forecast, 2024 – 2034
13.2.1.5.3.Asia Pacific
13.2.1.5.3.1.Market Estimation, 2016 – 2023
13.2.1.5.3.2.Market Forecast, 2024 – 2034
13.2.1.5.4.Middle East and Africa
13.2.1.5.4.1.Market Estimation, 2016 – 2023
13.2.1.5.4.2.Market Forecast, 2024 – 2034
13.2.1.5.5.Latin America
13.2.1.5.5.1.Market Estimation, 2016 – 2023
13.2.1.5.5.2.Market Forecast, 2024 – 2034
13.2.2.Diagnostic Centers
13.2.2.1.Definition
13.2.2.2.Market Estimation and Penetration, 2016 – 2023
13.2.2.3.Market Forecast, 2024 – 2034
13.2.2.4.Compound Annual Growth Rate (CAGR)
13.2.2.5.Regional Bifurcation
13.2.2.5.1.North America
13.2.2.5.1.1.Market Estimation, 2016 – 2023
13.2.2.5.1.2.Market Forecast, 2024 – 2034
13.2.2.5.2.Europe
13.2.2.5.2.1.Market Estimation, 2016 – 2023
13.2.2.5.2.2.Market Forecast, 2024 – 2034
13.2.2.5.3.Asia Pacific
13.2.2.5.3.1.Market Estimation, 2016 – 2023
13.2.2.5.3.2.Market Forecast, 2024 – 2034
13.2.2.5.4.Middle East and Africa
13.2.2.5.4.1.Market Estimation, 2016 – 2023
13.2.2.5.4.2.Market Forecast, 2024 – 2034
13.2.2.5.5.Latin America
13.2.2.5.5.1.Market Estimation, 2016 – 2023
13.2.2.5.5.2.Market Forecast, 2024 – 2034
13.2.3.Others
13.2.3.1.Definition
13.2.3.2.Market Estimation and Penetration, 2016 – 2023
13.2.3.3.Market Forecast, 2024 – 2034
13.2.3.4.Compound Annual Growth Rate (CAGR)
13.2.3.5.Regional Bifurcation
13.2.3.5.1.North America
13.2.3.5.1.1.Market Estimation, 2016 – 2023
13.2.3.5.1.2.Market Forecast, 2024 – 2034
13.2.3.5.2.Europe
13.2.3.5.2.1.Market Estimation, 2016 – 2023
13.2.3.5.2.2.Market Forecast, 2024 – 2034
13.2.3.5.3.Asia Pacific
13.2.3.5.3.1.Market Estimation, 2016 – 2023
13.2.3.5.3.2.Market Forecast, 2024 – 2034
13.2.3.5.4.Middle East and Africa
13.2.3.5.4.1.Market Estimation, 2016 – 2023
13.2.3.5.4.2.Market Forecast, 2024 – 2034
13.2.3.5.5.Latin America
13.2.3.5.5.1.Market Estimation, 2016 – 2023
13.2.3.5.5.2.Market Forecast, 2024 – 2034
13.3.Key Segment for Channeling Investments
13.3.1.By End User
14.North America Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
14.1.Overview
14.1.1.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn)
14.2.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
14.2.1.CT
14.2.2.Mammography
14.2.3.MRI
14.2.4.Ultrasound
14.2.5.X-Rays
14.2.6.PET
14.3.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
14.3.1.Cloud
14.3.2.On-Premises
14.3.3.Hybrid
14.4.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
14.4.1.VNA
14.4.1.1.Department VNA
14.4.1.2.Multi-Department VNA
14.4.1.3.Multi-Site VNA
14.4.2.PACS
14.4.2.1.Department PACS
14.4.2.2.Multi-Department PACS
14.4.2.3.Multi-Site PACS
14.5.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
14.5.1.Independent Vendor
14.5.2.Third-party Vendor
14.6.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
14.6.1.Cardiology
14.6.2.Orthopedic
14.6.3.Oncology
14.6.4.Neurology
14.6.5.Obstetrics and Gynecology
14.6.6.Others
14.7.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
14.7.1.Hospitals and Clinics
14.7.2.Diagnostic Centers
14.7.3.Others
14.8.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
14.8.1.U.S
14.8.1.1.U.S Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
14.8.1.1.1.CT
14.8.1.1.2.Mammography
14.8.1.1.3.MRI
14.8.1.1.4.Ultrasound
14.8.1.1.5.X-Rays
14.8.1.1.6.PET
14.8.1.2.U.S Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
14.8.1.2.1.Cloud
14.8.1.2.2.On-Premises
14.8.1.2.3.Hybrid
14.8.1.3.U.S Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
14.8.1.3.1.VNA
14.8.1.3.1.1.Department VNA
14.8.1.3.1.2.Multi-Department VNA
14.8.1.3.1.3.Multi-Site VNA
14.8.1.3.2.PACS
14.8.1.3.2.1.Department PACS
14.8.1.3.2.2.Multi-Department PACS
14.8.1.3.2.3.Multi-Site PACS
14.8.1.4.U.S Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
14.8.1.4.1.Independent Vendor
14.8.1.4.2.Third-party Vendor
14.8.1.5.U.S Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
14.8.1.5.1.Cardiology
14.8.1.5.2.Orthopedic
14.8.1.5.3.Oncology
14.8.1.5.4.Neurology
14.8.1.5.5.Obstetrics and Gynecology
14.8.1.5.6.Others
14.8.1.6.U.S Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
14.8.1.6.1.Hospitals and Clinics
14.8.1.6.2.Diagnostic Centers
14.8.1.6.3.Others
14.8.2.Canada
14.8.2.1.Canada Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
14.8.2.1.1.CT
14.8.2.1.2.Mammography
14.8.2.1.3.MRI
14.8.2.1.4.Ultrasound
14.8.2.1.5.X-Rays
14.8.2.1.6.PET
14.8.2.2.Canada Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
14.8.2.2.1.Cloud
14.8.2.2.2.On-Premises
14.8.2.2.3.Hybrid
14.8.2.3.Canada Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
14.8.2.3.1.VNA
14.8.2.3.1.1.Department VNA
14.8.2.3.1.2.Multi-Department VNA
14.8.2.3.1.3.Multi-Site VNA
14.8.2.3.2.PACS
14.8.2.3.2.1.Department PACS
14.8.2.3.2.2.Multi-Department PACS
14.8.2.3.2.3.Multi-Site PACS
14.8.2.4.Canada Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
14.8.2.4.1.Independent Vendor
14.8.2.4.2.Third-party Vendor
14.8.2.5.Canada Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
14.8.2.5.1.Cardiology
14.8.2.5.2.Orthopedic
14.8.2.5.3.Oncology
14.8.2.5.4.Neurology
14.8.2.5.5.Obstetrics and Gynecology
14.8.2.5.6.Others
14.8.2.6.Canada Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
14.8.2.6.1.Hospitals and Clinics
14.8.2.6.2.Diagnostic Centers
14.8.2.6.3.Others
14.8.3.Mexico
14.8.3.1.Mexico Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
14.8.3.1.1.CT
14.8.3.1.2.Mammography
14.8.3.1.3.MRI
14.8.3.1.4.Ultrasound
14.8.3.1.5.X-Rays
14.8.3.1.6.PET
14.8.3.2.Mexico Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
14.8.3.2.1.Cloud
14.8.3.2.2.On-Premises
14.8.3.2.3.Hybrid
14.8.3.3.Mexico Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
14.8.3.3.1.VNA
14.8.3.3.1.1.Department VNA
14.8.3.3.1.2.Multi-Department VNA
14.8.3.3.1.3.Multi-Site VNA
14.8.3.3.2.PACS
14.8.3.3.2.1.Department PACS
14.8.3.3.2.2.Multi-Department PACS
14.8.3.3.2.3.Multi-Site PACS
14.8.3.4.Mexico Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
14.8.3.4.1.Independent Vendor
14.8.3.4.2.Third-party Vendor
14.8.3.5.Mexico Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
14.8.3.5.1.Cardiology
14.8.3.5.2.Orthopedic
14.8.3.5.3.Oncology
14.8.3.5.4.Neurology
14.8.3.5.5.Obstetrics and Gynecology
14.8.3.5.6.Others
14.8.3.6.Mexico Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
14.8.3.6.1.Hospitals and Clinics
14.8.3.6.2.Diagnostic Centers
14.8.3.6.3.Others
14.8.4.Rest of North America
14.8.4.1.Rest of North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
14.8.4.1.1.CT
14.8.4.1.2.Mammography
14.8.4.1.3.MRI
14.8.4.1.4.Ultrasound
14.8.4.1.5.X-Rays
14.8.4.1.6.PET
14.8.4.2.Rest of North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
14.8.4.2.1.Cloud
14.8.4.2.2.On-Premises
14.8.4.2.3.Hybrid
14.8.4.3.Rest of North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
14.8.4.3.1.VNA
14.8.4.3.1.1.Department VNA
14.8.4.3.1.2.Multi-Department VNA
14.8.4.3.1.3.Multi-Site VNA
14.8.4.3.2.PACS
14.8.4.3.2.1.Department PACS
14.8.4.3.2.2.Multi-Department PACS
14.8.4.3.2.3.Multi-Site PACS
14.8.4.4.Rest of North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
14.8.4.4.1.Independent Vendor
14.8.4.4.2.Third-party Vendor
14.8.4.5.Rest of North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
14.8.4.5.1.Cardiology
14.8.4.5.2.Orthopedic
14.8.4.5.3.Oncology
14.8.4.5.4.Neurology
14.8.4.5.5.Obstetrics and Gynecology
14.8.4.5.6.Others
14.8.4.6.Rest of North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
14.8.4.6.1.Hospitals and Clinics
14.8.4.6.2.Diagnostic Centers
14.8.4.6.3.Others
14.9.Key Segment for Channeling Investments
14.9.1.By Country
14.9.2.By Modality
14.9.3.By Deployment
14.9.4.By Product Type
14.9.5.By Vendor Type
14.9.6.By Application
14.9.7.By End User
15.Europe Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
15.1.Overview
15.1.1.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn)
15.2.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.2.1.CT
15.2.2.Mammography
15.2.3.MRI
15.2.4.Ultrasound
15.2.5.X-Rays
15.2.6.PET
15.3.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.3.1.Cloud
15.3.2.On-Premises
15.3.3.Hybrid
15.4.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.4.1.VNA
15.4.1.1.Department VNA
15.4.1.2.Multi-Department VNA
15.4.1.3.Multi-Site VNA
15.4.2.PACS
15.4.2.1.Department PACS
15.4.2.2.Multi-Department PACS
15.4.2.3.Multi-Site PACS
15.5.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.5.1.Independent Vendor
15.5.2.Third-party Vendor
15.6.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.6.1.Cardiology
15.6.2.Orthopedic
15.6.3.Oncology
15.6.4.Neurology
15.6.5.Obstetrics and Gynecology
15.6.6.Others
15.7.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.7.1.Hospitals and Clinics
15.7.2.Diagnostic Centers
15.7.3.Others
15.8.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
15.8.1.France
15.8.1.1.France Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.1.1.1.CT
15.8.1.1.2.Mammography
15.8.1.1.3.MRI
15.8.1.1.4.Ultrasound
15.8.1.1.5.X-Rays
15.8.1.1.6.PET
15.8.1.2.France Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.1.2.1.Cloud
15.8.1.2.2.On-Premises
15.8.1.2.3.Hybrid
15.8.1.3.France Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.1.3.1.VNA
15.8.1.3.1.1.Department VNA
15.8.1.3.1.2.Multi-Department VNA
15.8.1.3.1.3.Multi-Site VNA
15.8.1.3.2.PACS
15.8.1.3.2.1.Department PACS
15.8.1.3.2.2.Multi-Department PACS
15.8.1.3.2.3.Multi-Site PACS
15.8.1.4.France Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.1.4.1.Independent Vendor
15.8.1.4.2.Third-party Vendor
15.8.1.5.France Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.1.5.1.Cardiology
15.8.1.5.2.Orthopedic
15.8.1.5.3.Oncology
15.8.1.5.4.Neurology
15.8.1.5.5.Obstetrics and Gynecology
15.8.1.5.6.Others
15.8.1.6.France Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.1.6.1.Hospitals and Clinics
15.8.1.6.2.Diagnostic Centers
15.8.1.6.3.Others
15.8.2.The UK
15.8.2.1.The UK Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.2.1.1.CT
15.8.2.1.2.Mammography
15.8.2.1.3.MRI
15.8.2.1.4.Ultrasound
15.8.2.1.5.X-Rays
15.8.2.1.6.PET
15.8.2.2.The UK Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.2.2.1.Cloud
15.8.2.2.2.On-Premises
15.8.2.2.3.Hybrid
15.8.2.3.The UK Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.2.3.1.VNA
15.8.2.3.1.1.Department VNA
15.8.2.3.1.2.Multi-Department VNA
15.8.2.3.1.3.Multi-Site VNA
15.8.2.3.2.PACS
15.8.2.3.2.1.Department PACS
15.8.2.3.2.2.Multi-Department PACS
15.8.2.3.2.3.Multi-Site PACS
15.8.2.4.The UK Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.2.4.1.Independent Vendor
15.8.2.4.2.Third-party Vendor
15.8.2.5.The UK Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.2.5.1.Cardiology
15.8.2.5.2.Orthopedic
15.8.2.5.3.Oncology
15.8.2.5.4.Neurology
15.8.2.5.5.Obstetrics and Gynecology
15.8.2.5.6.Others
15.8.2.6.The UK Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.2.6.1.Hospitals and Clinics
15.8.2.6.2.Diagnostic Centers
15.8.2.6.3.Others
15.8.3.Spain
15.8.3.1.Spain Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.3.1.1.CT
15.8.3.1.2.Mammography
15.8.3.1.3.MRI
15.8.3.1.4.Ultrasound
15.8.3.1.5.X-Rays
15.8.3.1.6.PET
15.8.3.2.Spain Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.3.2.1.Cloud
15.8.3.2.2.On-Premises
15.8.3.2.3.Hybrid
15.8.3.3.Spain Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.3.3.1.VNA
15.8.3.3.1.1.Department VNA
15.8.3.3.1.2.Multi-Department VNA
15.8.3.3.1.3.Multi-Site VNA
15.8.3.3.2.PACS
15.8.3.3.2.1.Department PACS
15.8.3.3.2.2.Multi-Department PACS
15.8.3.3.2.3.Multi-Site PACS
15.8.3.4.Spain Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.3.4.1.Independent Vendor
15.8.3.4.2.Third-party Vendor
15.8.3.5.Spain Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.3.5.1.Cardiology
15.8.3.5.2.Orthopedic
15.8.3.5.3.Oncology
15.8.3.5.4.Neurology
15.8.3.5.5.Obstetrics and Gynecology
15.8.3.5.6.Others
15.8.3.6.Spain Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.3.6.1.Hospitals and Clinics
15.8.3.6.2.Diagnostic Centers
15.8.3.6.3.Others
15.8.4.Germany
15.8.4.1.Germany Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.4.1.1.CT
15.8.4.1.2.Mammography
15.8.4.1.3.MRI
15.8.4.1.4.Ultrasound
15.8.4.1.5.X-Rays
15.8.4.1.6.PET
15.8.4.2.Germany Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.4.2.1.Cloud
15.8.4.2.2.On-Premises
15.8.4.2.3.Hybrid
15.8.4.3.Germany Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.4.3.1.VNA
15.8.4.3.1.1.Department VNA
15.8.4.3.1.2.Multi-Department VNA
15.8.4.3.1.3.Multi-Site VNA
15.8.4.3.2.PACS
15.8.4.3.2.1.Department PACS
15.8.4.3.2.2.Multi-Department PACS
15.8.4.3.2.3.Multi-Site PACS
15.8.4.4.Germany Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.4.4.1.Independent Vendor
15.8.4.4.2.Third-party Vendor
15.8.4.5.Germany Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.4.5.1.Cardiology
15.8.4.5.2.Orthopedic
15.8.4.5.3.Oncology
15.8.4.5.4.Neurology
15.8.4.5.5.Obstetrics and Gynecology
15.8.4.5.6.Others
15.8.4.6.Germany Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.4.6.1.Hospitals and Clinics
15.8.4.6.2.Diagnostic Centers
15.8.4.6.3.Others
15.8.5.Italy
15.8.5.1.Italy Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.5.1.1.CT
15.8.5.1.2.Mammography
15.8.5.1.3.MRI
15.8.5.1.4.Ultrasound
15.8.5.1.5.X-Rays
15.8.5.1.6.PET
15.8.5.2.Italy Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.5.2.1.Cloud
15.8.5.2.2.On-Premises
15.8.5.2.3.Hybrid
15.8.5.3.Italy Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.5.3.1.VNA
15.8.5.3.1.1.Department VNA
15.8.5.3.1.2.Multi-Department VNA
15.8.5.3.1.3.Multi-Site VNA
15.8.5.3.2.PACS
15.8.5.3.2.1.Department PACS
15.8.5.3.2.2.Multi-Department PACS
15.8.5.3.2.3.Multi-Site PACS
15.8.5.4.Italy Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.5.4.1.Independent Vendor
15.8.5.4.2.Third-party Vendor
15.8.5.5.Italy Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.5.5.1.Cardiology
15.8.5.5.2.Orthopedic
15.8.5.5.3.Oncology
15.8.5.5.4.Neurology
15.8.5.5.5.Obstetrics and Gynecology
15.8.5.5.6.Others
15.8.5.6.Italy Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.5.6.1.Hospitals and Clinics
15.8.5.6.2.Diagnostic Centers
15.8.5.6.3.Others
15.8.6.Nordic Countries
15.8.6.1.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.6.1.1.CT
15.8.6.1.2.Mammography
15.8.6.1.3.MRI
15.8.6.1.4.Ultrasound
15.8.6.1.5.X-Rays
15.8.6.1.6.PET
15.8.6.2.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.6.2.1.Cloud
15.8.6.2.2.On-Premises
15.8.6.2.3.Hybrid
15.8.6.3.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.6.3.1.VNA
15.8.6.3.1.1.Department VNA
15.8.6.3.1.2.Multi-Department VNA
15.8.6.3.1.3.Multi-Site VNA
15.8.6.3.2.PACS
15.8.6.3.2.1.Department PACS
15.8.6.3.2.2.Multi-Department PACS
15.8.6.3.2.3.Multi-Site PACS
15.8.6.4.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.6.4.1.Independent Vendor
15.8.6.4.2.Third-party Vendor
15.8.6.5.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.6.5.1.Cardiology
15.8.6.5.2.Orthopedic
15.8.6.5.3.Oncology
15.8.6.5.4.Neurology
15.8.6.5.5.Obstetrics and Gynecology
15.8.6.5.6.Others
15.8.6.6.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.6.6.1.Hospitals and Clinics
15.8.6.6.2.Diagnostic Centers
15.8.6.6.3.Others
15.8.6.7.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
15.8.6.7.1.Denmark
15.8.6.7.2.Finland
15.8.6.7.3.Iceland
15.8.6.7.4.Sweden
15.8.6.7.5.Norway
15.8.7.Benelux Union
15.8.7.1.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.7.1.1.CT
15.8.7.1.2.Mammography
15.8.7.1.3.MRI
15.8.7.1.4.Ultrasound
15.8.7.1.5.X-Rays
15.8.7.1.6.PET
15.8.7.2.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.7.2.1.Cloud
15.8.7.2.2.On-Premises
15.8.7.2.3.Hybrid
15.8.7.3.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.7.3.1.VNA
15.8.7.3.1.1.Department VNA
15.8.7.3.1.2.Multi-Department VNA
15.8.7.3.1.3.Multi-Site VNA
15.8.7.3.2.PACS
15.8.7.3.2.1.Department PACS
15.8.7.3.2.2.Multi-Department PACS
15.8.7.3.2.3.Multi-Site PACS
15.8.7.4.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.7.4.1.Independent Vendor
15.8.7.4.2.Third-party Vendor
15.8.7.5.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.7.5.1.Cardiology
15.8.7.5.2.Orthopedic
15.8.7.5.3.Oncology
15.8.7.5.4.Neurology
15.8.7.5.5.Obstetrics and Gynecology
15.8.7.5.6.Others
15.8.7.6.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.7.6.1.Hospitals and Clinics
15.8.7.6.2.Diagnostic Centers
15.8.7.6.3.Others
15.8.7.7.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
15.8.7.7.1.Belgium
15.8.7.7.2.The Netherlands
15.8.7.7.3.Luxembourg
15.8.8.Rest of Europe
15.8.8.1.Rest of Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.8.1.1.CT
15.8.8.1.2.Mammography
15.8.8.1.3.MRI
15.8.8.1.4.Ultrasound
15.8.8.1.5.X-Rays
15.8.8.1.6.PET
15.8.8.2.Rest of Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.8.2.1.Cloud
15.8.8.2.2.On-Premises
15.8.8.2.3.Hybrid
15.8.8.3.Rest of Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.8.3.1.VNA
15.8.8.3.1.1.Department VNA
15.8.8.3.1.2.Multi-Department VNA
15.8.8.3.1.3.Multi-Site VNA
15.8.8.3.2.PACS
15.8.8.3.2.1.Department PACS
15.8.8.3.2.2.Multi-Department PACS
15.8.8.3.2.3.Multi-Site PACS
15.8.8.4.Rest of Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.8.4.1.Independent Vendor
15.8.8.4.2.Third-party Vendor
15.8.8.5.Rest of Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.8.5.1.Cardiology
15.8.8.5.2.Orthopedic
15.8.8.5.3.Oncology
15.8.8.5.4.Neurology
15.8.8.5.5.Obstetrics and Gynecology
15.8.8.5.6.Others
15.8.8.6.Rest of Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.8.6.1.Hospitals and Clinics
15.8.8.6.2.Diagnostic Centers
15.8.8.6.3.Others
15.9.Key Segment for Channeling Investments
15.9.1.By Country
15.9.2.By Modality
15.9.3.By Deployment
15.9.4.By Product Type
15.9.5.By Vendor Type
15.9.6.By Application
15.9.7.By End User
16.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
16.1.Overview
16.1.1.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn)
16.2.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.2.1.CT
16.2.2.Mammography
16.2.3.MRI
16.2.4.Ultrasound
16.2.5.X-Rays
16.2.6.PET
16.3.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.3.1.Cloud
16.3.2.On-Premises
16.3.3.Hybrid
16.4.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.4.1.VNA
16.4.1.1.Department VNA
16.4.1.2.Multi-Department VNA
16.4.1.3.Multi-Site VNA
16.4.2.PACS
16.4.2.1.Department PACS
16.4.2.2.Multi-Department PACS
16.4.2.3.Multi-Site PACS
16.5.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.5.1.Independent Vendor
16.5.2.Third-party Vendor
16.6.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.6.1.Cardiology
16.6.2.Orthopedic
16.6.3.Oncology
16.6.4.Neurology
16.6.5.Obstetrics and Gynecology
16.6.6.Others
16.7.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.7.1.Hospitals and Clinics
16.7.2.Diagnostic Centers
16.7.3.Others
16.8.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
16.8.1.China
16.8.1.1.China Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.1.1.1.CT
16.8.1.1.2.Mammography
16.8.1.1.3.MRI
16.8.1.1.4.Ultrasound
16.8.1.1.5.X-Rays
16.8.1.1.6.PET
16.8.1.2.China Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.1.2.1.Cloud
16.8.1.2.2.On-Premises
16.8.1.2.3.Hybrid
16.8.1.3.China Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.1.3.1.VNA
16.8.1.3.1.1.Department VNA
16.8.1.3.1.2.Multi-Department VNA
16.8.1.3.1.3.Multi-Site VNA
16.8.1.3.2.PACS
16.8.1.3.2.1.Department PACS
16.8.1.3.2.2.Multi-Department PACS
16.8.1.3.2.3.Multi-Site PACS
16.8.1.4.China Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.1.4.1.Independent Vendor
16.8.1.4.2.Third-party Vendor
16.8.1.5.China Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.1.5.1.Cardiology
16.8.1.5.2.Orthopedic
16.8.1.5.3.Oncology
16.8.1.5.4.Neurology
16.8.1.5.5.Obstetrics and Gynecology
16.8.1.5.6.Others
16.8.1.6.China Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.1.6.1.Hospitals and Clinics
16.8.1.6.2.Diagnostic Centers
16.8.1.6.3.Others
16.8.2.Japan
16.8.2.1.Japan Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.2.1.1.CT
16.8.2.1.2.Mammography
16.8.2.1.3.MRI
16.8.2.1.4.Ultrasound
16.8.2.1.5.X-Rays
16.8.2.1.6.PET
16.8.2.2.Japan Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.2.2.1.Cloud
16.8.2.2.2.On-Premises
16.8.2.2.3.Hybrid
16.8.2.3.Japan Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.2.3.1.VNA
16.8.2.3.1.1.Department VNA
16.8.2.3.1.2.Multi-Department VNA
16.8.2.3.1.3.Multi-Site VNA
16.8.2.3.2.PACS
16.8.2.3.2.1.Department PACS
16.8.2.3.2.2.Multi-Department PACS
16.8.2.3.2.3.Multi-Site PACS
16.8.2.4.Japan Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.2.4.1.Independent Vendor
16.8.2.4.2.Third-party Vendor
16.8.2.5.Japan Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.2.5.1.Cardiology
16.8.2.5.2.Orthopedic
16.8.2.5.3.Oncology
16.8.2.5.4.Neurology
16.8.2.5.5.Obstetrics and Gynecology
16.8.2.5.6.Others
16.8.2.6.Japan Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.2.6.1.Hospitals and Clinics
16.8.2.6.2.Diagnostic Centers
16.8.2.6.3.Others
16.8.3.India
16.8.3.1.India Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.3.1.1.CT
16.8.3.1.2.Mammography
16.8.3.1.3.MRI
16.8.3.1.4.Ultrasound
16.8.3.1.5.X-Rays
16.8.3.1.6.PET
16.8.3.2.India Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.3.2.1.Cloud
16.8.3.2.2.On-Premises
16.8.3.2.3.Hybrid
16.8.3.3.India Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.3.3.1.VNA
16.8.3.3.1.1.Department VNA
16.8.3.3.1.2.Multi-Department VNA
16.8.3.3.1.3.Multi-Site VNA
16.8.3.3.2.PACS
16.8.3.3.2.1.Department PACS
16.8.3.3.2.2.Multi-Department PACS
16.8.3.3.2.3.Multi-Site PACS
16.8.3.4.India Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.3.4.1.Independent Vendor
16.8.3.4.2.Third-party Vendor
16.8.3.5.India Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.3.5.1.Cardiology
16.8.3.5.2.Orthopedic
16.8.3.5.3.Oncology
16.8.3.5.4.Neurology
16.8.3.5.5.Obstetrics and Gynecology
16.8.3.5.6.Others
16.8.3.6.India Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.3.6.1.Hospitals and Clinics
16.8.3.6.2.Diagnostic Centers
16.8.3.6.3.Others
16.8.4.New Zealand
16.8.4.1.New Zealand Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.4.1.1.CT
16.8.4.1.2.Mammography
16.8.4.1.3.MRI
16.8.4.1.4.Ultrasound
16.8.4.1.5.X-Rays
16.8.4.1.6.PET
16.8.4.2.New Zealand Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.4.2.1.Cloud
16.8.4.2.2.On-Premises
16.8.4.2.3.Hybrid
16.8.4.3.New Zealand Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.4.3.1.VNA
16.8.4.3.1.1.Department VNA
16.8.4.3.1.2.Multi-Department VNA
16.8.4.3.1.3.Multi-Site VNA
16.8.4.3.2.PACS
16.8.4.3.2.1.Department PACS
16.8.4.3.2.2.Multi-Department PACS
16.8.4.3.2.3.Multi-Site PACS
16.8.4.4.New Zealand Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.4.4.1.Independent Vendor
16.8.4.4.2.Third-party Vendor
16.8.4.5.New Zealand Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.4.5.1.Cardiology
16.8.4.5.2.Orthopedic
16.8.4.5.3.Oncology
16.8.4.5.4.Neurology
16.8.4.5.5.Obstetrics and Gynecology
16.8.4.5.6.Others
16.8.4.6.New Zealand Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.4.6.1.Hospitals and Clinics
16.8.4.6.2.Diagnostic Centers
16.8.4.6.3.Others
16.8.5.Australia
16.8.5.1.Australia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.5.1.1.CT
16.8.5.1.2.Mammography
16.8.5.1.3.MRI
16.8.5.1.4.Ultrasound
16.8.5.1.5.X-Rays
16.8.5.1.6.PET
16.8.5.2.Australia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.5.2.1.Cloud
16.8.5.2.2.On-Premises
16.8.5.2.3.Hybrid
16.8.5.3.Australia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.5.3.1.VNA
16.8.5.3.1.1.Department VNA
16.8.5.3.1.2.Multi-Department VNA
16.8.5.3.1.3.Multi-Site VNA
16.8.5.3.2.PACS
16.8.5.3.2.1.Department PACS
16.8.5.3.2.2.Multi-Department PACS
16.8.5.3.2.3.Multi-Site PACS
16.8.5.4.Australia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.5.4.1.Independent Vendor
16.8.5.4.2.Third-party Vendor
16.8.5.5.Australia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.5.5.1.Cardiology
16.8.5.5.2.Orthopedic
16.8.5.5.3.Oncology
16.8.5.5.4.Neurology
16.8.5.5.5.Obstetrics and Gynecology
16.8.5.5.6.Others
16.8.5.6.Australia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.5.6.1.Hospitals and Clinics
16.8.5.6.2.Diagnostic Centers
16.8.5.6.3.Others
16.8.6.South Korea
16.8.6.1.South Korea Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.6.1.1.CT
16.8.6.1.2.Mammography
16.8.6.1.3.MRI
16.8.6.1.4.Ultrasound
16.8.6.1.5.X-Rays
16.8.6.1.6.PET
16.8.6.2.South Korea Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.6.2.1.Cloud
16.8.6.2.2.On-Premises
16.8.6.2.3.Hybrid
16.8.6.3.South Korea Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.6.3.1.VNA
16.8.6.3.1.1.Department VNA
16.8.6.3.1.2.Multi-Department VNA
16.8.6.3.1.3.Multi-Site VNA
16.8.6.3.2.PACS
16.8.6.3.2.1.Department PACS
16.8.6.3.2.2.Multi-Department PACS
16.8.6.3.2.3.Multi-Site PACS
16.8.6.4.South Korea Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.6.4.1.Independent Vendor
16.8.6.4.2.Third-party Vendor
16.8.6.5.South Korea Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.6.5.1.Cardiology
16.8.6.5.2.Orthopedic
16.8.6.5.3.Oncology
16.8.6.5.4.Neurology
16.8.6.5.5.Obstetrics and Gynecology
16.8.6.5.6.Others
16.8.6.6.South Korea Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.6.6.1.Hospitals and Clinics
16.8.6.6.2.Diagnostic Centers
16.8.6.6.3.Others
16.8.7.Southeast Asia
16.8.7.1.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.7.1.1.CT
16.8.7.1.2.Mammography
16.8.7.1.3.MRI
16.8.7.1.4.Ultrasound
16.8.7.1.5.X-Rays
16.8.7.1.6.PET
16.8.7.2.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.7.2.1.Cloud
16.8.7.2.2.On-Premises
16.8.7.2.3.Hybrid
16.8.7.3.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.7.3.1.VNA
16.8.7.3.1.1.Department VNA
16.8.7.3.1.2.Multi-Department VNA
16.8.7.3.1.3.Multi-Site VNA
16.8.7.3.2.PACS
16.8.7.3.2.1.Department PACS
16.8.7.3.2.2.Multi-Department PACS
16.8.7.3.2.3.Multi-Site PACS
16.8.7.4.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.7.4.1.Independent Vendor
16.8.7.4.2.Third-party Vendor
16.8.7.5.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.7.5.1.Cardiology
16.8.7.5.2.Orthopedic
16.8.7.5.3.Oncology
16.8.7.5.4.Neurology
16.8.7.5.5.Obstetrics and Gynecology
16.8.7.5.6.Others
16.8.7.6.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.7.6.1.Hospitals and Clinics
16.8.7.6.2.Diagnostic Centers
16.8.7.6.3.Others
16.8.7.7.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
16.8.7.7.1.Indonesia
16.8.7.7.2.Thailand
16.8.7.7.3.Malaysia
16.8.7.7.4.Singapore
16.8.7.7.5.Rest of Southeast Asia
16.8.8.Rest of Asia Pacific
16.8.8.1.Rest of Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.8.1.1.CT
16.8.8.1.2.Mammography
16.8.8.1.3.MRI
16.8.8.1.4.Ultrasound
16.8.8.1.5.X-Rays
16.8.8.1.6.PET
16.8.8.2.Rest of Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.8.2.1.Cloud
16.8.8.2.2.On-Premises
16.8.8.2.3.Hybrid
16.8.8.3.Rest of Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.8.3.1.VNA
16.8.8.3.1.1.Department VNA
16.8.8.3.1.2.Multi-Department VNA
16.8.8.3.1.3.Multi-Site VNA
16.8.8.3.2.PACS
16.8.8.3.2.1.Department PACS
16.8.8.3.2.2.Multi-Department PACS
16.8.8.3.2.3.Multi-Site PACS
16.8.8.4.Rest of Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.8.4.1.Independent Vendor
16.8.8.4.2.Third-party Vendor
16.8.8.5.Rest of Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.8.5.1.Cardiology
16.8.8.5.2.Orthopedic
16.8.8.5.3.Oncology
16.8.8.5.4.Neurology
16.8.8.5.5.Obstetrics and Gynecology
16.8.8.5.6.Others
16.8.8.6.Rest of Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.8.6.1.Hospitals and Clinics
16.8.8.6.2.Diagnostic Centers
16.8.8.6.3.Others
16.9.Key Segment for Channeling Investments
16.9.1.By Country
16.9.2.By Modality
16.9.3.By Deployment
16.9.4.By Product Type
16.9.5.By Vendor Type
16.9.6.By Application
16.9.7.By End User
17.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
17.1.Overview
17.1.1.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn)
17.2.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.2.1.CT
17.2.2.Mammography
17.2.3.MRI
17.2.4.Ultrasound
17.2.5.X-Rays
17.2.6.PET
17.3.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.3.1.Cloud
17.3.2.On-Premises
17.3.3.Hybrid
17.4.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.4.1.VNA
17.4.1.1.Department VNA
17.4.1.2.Multi-Department VNA
17.4.1.3.Multi-Site VNA
17.4.2.PACS
17.4.2.1.Department PACS
17.4.2.2.Multi-Department PACS
17.4.2.3.Multi-Site PACS
17.5.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.5.1.Independent Vendor
17.5.2.Third-party Vendor
17.6.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.6.1.Cardiology
17.6.2.Orthopedic
17.6.3.Oncology
17.6.4.Neurology
17.6.5.Obstetrics and Gynecology
17.6.6.Others
17.7.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.7.1.Hospitals and Clinics
17.7.2.Diagnostic Centers
17.7.3.Others
17.8.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
17.8.1.Saudi Arabia
17.8.1.1.Saudi Arabia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.8.1.1.1.CT
17.8.1.1.2.Mammography
17.8.1.1.3.MRI
17.8.1.1.4.Ultrasound
17.8.1.1.5.X-Rays
17.8.1.1.6.PET
17.8.1.2.Saudi Arabia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.8.1.2.1.Cloud
17.8.1.2.2.On-Premises
17.8.1.2.3.Hybrid
17.8.1.3.Saudi Arabia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.8.1.3.1.VNA
17.8.1.3.1.1.Department VNA
17.8.1.3.1.2.Multi-Department VNA
17.8.1.3.1.3.Multi-Site VNA
17.8.1.3.2.PACS
17.8.1.3.2.1.Department PACS
17.8.1.3.2.2.Multi-Department PACS
17.8.1.3.2.3.Multi-Site PACS
17.8.1.4.Saudi Arabia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.8.1.4.1.Independent Vendor
17.8.1.4.2.Third-party Vendor
17.8.1.5.Saudi Arabia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.8.1.5.1.Cardiology
17.8.1.5.2.Orthopedic
17.8.1.5.3.Oncology
17.8.1.5.4.Neurology
17.8.1.5.5.Obstetrics and Gynecology
17.8.1.5.6.Others
17.8.1.6.Saudi Arabia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.8.1.6.1.Hospitals and Clinics
17.8.1.6.2.Diagnostic Centers
17.8.1.6.3.Others
17.8.2.UAE
17.8.2.1.UAE Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.8.2.1.1.CT
17.8.2.1.2.Mammography
17.8.2.1.3.MRI
17.8.2.1.4.Ultrasound
17.8.2.1.5.X-Rays
17.8.2.1.6.PET
17.8.2.2.UAE Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.8.2.2.1.Cloud
17.8.2.2.2.On-Premises
17.8.2.2.3.Hybrid
17.8.2.3.UAE Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.8.2.3.1.VNA
17.8.2.3.1.1.Department VNA
17.8.2.3.1.2.Multi-Department VNA
17.8.2.3.1.3.Multi-Site VNA
17.8.2.3.2.PACS
17.8.2.3.2.1.Department PACS
17.8.2.3.2.2.Multi-Department PACS
17.8.2.3.2.3.Multi-Site PACS
17.8.2.4.UAE Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.8.2.4.1.Independent Vendor
17.8.2.4.2.Third-party Vendor
17.8.2.5.UAE Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.8.2.5.1.Cardiology
17.8.2.5.2.Orthopedic
17.8.2.5.3.Oncology
17.8.2.5.4.Neurology
17.8.2.5.5.Obstetrics and Gynecology
17.8.2.5.6.Others
17.8.2.6.UAE Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.8.2.6.1.Hospitals and Clinics
17.8.2.6.2.Diagnostic Centers
17.8.2.6.3.Others
17.8.3.Egypt
17.8.3.1.Egypt Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.8.3.1.1.CT
17.8.3.1.2.Mammography
17.8.3.1.3.MRI
17.8.3.1.4.Ultrasound
17.8.3.1.5.X-Rays
17.8.3.1.6.PET
17.8.3.2.Egypt Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.8.3.2.1.Cloud
17.8.3.2.2.On-Premises
17.8.3.2.3.Hybrid
17.8.3.3.Egypt Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.8.3.3.1.VNA
17.8.3.3.1.1.Department VNA
17.8.3.3.1.2.Multi-Department VNA
17.8.3.3.1.3.Multi-Site VNA
17.8.3.3.2.PACS
17.8.3.3.2.1.Department PACS
17.8.3.3.2.2.Multi-Department PACS
17.8.3.3.2.3.Multi-Site PACS
17.8.3.4.Egypt Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.8.3.4.1.Independent Vendor
17.8.3.4.2.Third-party Vendor
17.8.3.5.Egypt Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.8.3.5.1.Cardiology
17.8.3.5.2.Orthopedic
17.8.3.5.3.Oncology
17.8.3.5.4.Neurology
17.8.3.5.5.Obstetrics and Gynecology
17.8.3.5.6.Others
17.8.3.6.Egypt Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.8.3.6.1.Hospitals and Clinics
17.8.3.6.2.Diagnostic Centers
17.8.3.6.3.Others
17.8.4.Kuwait
17.8.4.1.Kuwait Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.8.4.1.1.CT
17.8.4.1.2.Mammography
17.8.4.1.3.MRI
17.8.4.1.4.Ultrasound
17.8.4.1.5.X-Rays
17.8.4.1.6.PET
17.8.4.2.Kuwait Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.8.4.2.1.Cloud
17.8.4.2.2.On-Premises
17.8.4.2.3.Hybrid
17.8.4.3.Kuwait Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.8.4.3.1.VNA
17.8.4.3.1.1.Department VNA
17.8.4.3.1.2.Multi-Department VNA
17.8.4.3.1.3.Multi-Site VNA
17.8.4.3.2.PACS
17.8.4.3.2.1.Department PACS
17.8.4.3.2.2.Multi-Department PACS
17.8.4.3.2.3.Multi-Site PACS
17.8.4.4.Kuwait Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.8.4.4.1.Independent Vendor
17.8.4.4.2.Third-party Vendor
17.8.4.5.Kuwait Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.8.4.5.1.Cardiology
17.8.4.5.2.Orthopedic
17.8.4.5.3.Oncology
17.8.4.5.4.Neurology
17.8.4.5.5.Obstetrics and Gynecology
17.8.4.5.6.Others
17.8.4.6.Kuwait Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.8.4.6.1.Hospitals and Clinics
17.8.4.6.2.Diagnostic Centers
17.8.4.6.3.Others
17.8.5.South Africa
17.8.5.1.South Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.8.5.1.1.CT
17.8.5.1.2.Mammography
17.8.5.1.3.MRI
17.8.5.1.4.Ultrasound
17.8.5.1.5.X-Rays
17.8.5.1.6.PET
17.8.5.2.South Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.8.5.2.1.Cloud
17.8.5.2.2.On-Premises
17.8.5.2.3.Hybrid
17.8.5.3.South Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.8.5.3.1.VNA
17.8.5.3.1.1.Department VNA
17.8.5.3.1.2.Multi-Department VNA
17.8.5.3.1.3.Multi-Site VNA
17.8.5.3.2.PACS
17.8.5.3.2.1.Department PACS
17.8.5.3.2.2.Multi-Department PACS
17.8.5.3.2.3.Multi-Site PACS
17.8.5.4.South Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.8.5.4.1.Independent Vendor
17.8.5.4.2.Third-party Vendor
17.8.5.5.South Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.8.5.5.1.Cardiology
17.8.5.5.2.Orthopedic
17.8.5.5.3.Oncology
17.8.5.5.4.Neurology
17.8.5.5.5.Obstetrics and Gynecology
17.8.5.5.6.Others
17.8.5.6.South Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.8.5.6.1.Hospitals and Clinics
17.8.5.6.2.Diagnostic Centers
17.8.5.6.3.Others
17.8.6.Rest of Middle East & Africa
17.8.6.1.Rest of Middle East & Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.8.6.1.1.CT
17.8.6.1.2.Mammography
17.8.6.1.3.MRI
17.8.6.1.4.Ultrasound
17.8.6.1.5.X-Rays
17.8.6.1.6.PET
17.8.6.2.Rest of Middle East & Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.8.6.2.1.Cloud
17.8.6.2.2.On-Premises
17.8.6.2.3.Hybrid
17.8.6.3.Rest of Middle East & Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.8.6.3.1.VNA
17.8.6.3.1.1.Department VNA
17.8.6.3.1.2.Multi-Department VNA
17.8.6.3.1.3.Multi-Site VNA
17.8.6.3.2.PACS
17.8.6.3.2.1.Department PACS
17.8.6.3.2.2.Multi-Department PACS
17.8.6.3.2.3.Multi-Site PACS
17.8.6.4.Rest of Middle East & Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.8.6.4.1.Independent Vendor
17.8.6.4.2.Third-party Vendor
17.8.6.5.Rest of Middle East & Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.8.6.5.1.Cardiology
17.8.6.5.2.Orthopedic
17.8.6.5.3.Oncology
17.8.6.5.4.Neurology
17.8.6.5.5.Obstetrics and Gynecology
17.8.6.5.6.Others
17.8.6.6.Rest of Middle East & Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.8.6.6.1.Hospitals and Clinics
17.8.6.6.2.Diagnostic Centers
17.8.6.6.3.Others
17.9.Key Segment for Channeling Investments
17.9.1.By Country
17.9.2.By Modality
17.9.3.By Deployment
17.9.4.By Product Type
17.9.5.By Vendor Type
17.9.6.By Application
17.9.7.By End User
18.Latin America Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
18.1.Overview
18.1.1.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn)
18.2.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
18.2.1.CT
18.2.2.Mammography
18.2.3.MRI
18.2.4.Ultrasound
18.2.5.X-Rays
18.2.6.PET
18.3.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
18.3.1.Cloud
18.3.2.On-Premises
18.3.3.Hybrid
18.4.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
18.4.1.VNA
18.4.1.1.Department VNA
18.4.1.2.Multi-Department VNA
18.4.1.3.Multi-Site VNA
18.4.2.PACS
18.4.2.1.Department PACS
18.4.2.2.Multi-Department PACS
18.4.2.3.Multi-Site PACS
18.5.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
18.5.1.Independent Vendor
18.5.2.Third-party Vendor
18.6.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
18.6.1.Cardiology
18.6.2.Orthopedic
18.6.3.Oncology
18.6.4.Neurology
18.6.5.Obstetrics and Gynecology
18.6.6.Others
18.7.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
18.7.1.Hospitals and Clinics
18.7.2.Diagnostic Centers
18.7.3.Others
18.8.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
18.8.1.Brazil
18.8.1.1.Brazil Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
18.8.1.1.1.CT
18.8.1.1.2.Mammography
18.8.1.1.3.MRI
18.8.1.1.4.Ultrasound
18.8.1.1.5.X-Rays
18.8.1.1.6.PET
18.8.1.2.Brazil Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
18.8.1.2.1.Cloud
18.8.1.2.2.On-Premises
18.8.1.2.3.Hybrid
18.8.1.3.Brazil Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
18.8.1.3.1.VNA
18.8.1.3.1.1.Department VNA
18.8.1.3.1.2.Multi-Department VNA
18.8.1.3.1.3.Multi-Site VNA
18.8.1.3.2.PACS
18.8.1.3.2.1.Department PACS
18.8.1.3.2.2.Multi-Department PACS
18.8.1.3.2.3.Multi-Site PACS
18.8.1.4.Brazil Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
18.8.1.4.1.Independent Vendor
18.8.1.4.2.Third-party Vendor
18.8.1.5.Brazil Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
18.8.1.5.1.Cardiology
18.8.1.5.2.Orthopedic
18.8.1.5.3.Oncology
18.8.1.5.4.Neurology
18.8.1.5.5.Obstetrics and Gynecology
18.8.1.5.6.Others
18.8.1.6.Brazil Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
18.8.1.6.1.Hospitals and Clinics
18.8.1.6.2.Diagnostic Centers
18.8.1.6.3.Others
18.8.2.Argentina
18.8.2.1.Argentina Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
18.8.2.1.1.CT
18.8.2.1.2.Mammography
18.8.2.1.3.MRI
18.8.2.1.4.Ultrasound
18.8.2.1.5.X-Rays
18.8.2.1.6.PET
18.8.2.2.Argentina Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
18.8.2.2.1.Cloud
18.8.2.2.2.On-Premises
18.8.2.2.3.Hybrid
18.8.2.3.Argentina Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
18.8.2.3.1.VNA
18.8.2.3.1.1.Department VNA
18.8.2.3.1.2.Multi-Department VNA
18.8.2.3.1.3.Multi-Site VNA
18.8.2.3.2.PACS
18.8.2.3.2.1.Department PACS
18.8.2.3.2.2.Multi-Department PACS
18.8.2.3.2.3.Multi-Site PACS
18.8.2.4.Argentina Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
18.8.2.4.1.Independent Vendor
18.8.2.4.2.Third-party Vendor
18.8.2.5.Argentina Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
18.8.2.5.1.Cardiology
18.8.2.5.2.Orthopedic
18.8.2.5.3.Oncology
18.8.2.5.4.Neurology
18.8.2.5.5.Obstetrics and Gynecology
18.8.2.5.6.Others
18.8.2.6.Argentina Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
18.8.2.6.1.Hospitals and Clinics
18.8.2.6.2.Diagnostic Centers
18.8.2.6.3.Others
18.8.3.Rest of Latin America
18.8.3.1.Rest of Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
18.8.3.1.1.CT
18.8.3.1.2.Mammography
18.8.3.1.3.MRI
18.8.3.1.4.Ultrasound
18.8.3.1.5.X-Rays
18.8.3.1.6.PET
18.8.3.2.Rest of Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
18.8.3.2.1.Cloud
18.8.3.2.2.On-Premises
18.8.3.2.3.Hybrid
18.8.3.3.Rest of Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
18.8.3.3.1.VNA
18.8.3.3.1.1.Department VNA
18.8.3.3.1.2.Multi-Department VNA
18.8.3.3.1.3.Multi-Site VNA
18.8.3.3.2.PACS
18.8.3.3.2.1.Department PACS
18.8.3.3.2.2.Multi-Department PACS
18.8.3.3.2.3.Multi-Site PACS
18.8.3.4.Rest of Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
18.8.3.4.1.Independent Vendor
18.8.3.4.2.Third-party Vendor
18.8.3.5.Rest of Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
18.8.3.5.1.Cardiology
18.8.3.5.2.Orthopedic
18.8.3.5.3.Oncology
18.8.3.5.4.Neurology
18.8.3.5.5.Obstetrics and Gynecology
18.8.3.5.6.Others
18.8.3.6.Rest of Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
18.8.3.6.1.Hospitals and Clinics
18.8.3.6.2.Diagnostic Centers
18.8.3.6.3.Others
18.9.Key Segment for Channeling Investments
18.9.1.By Country
18.9.2.By Modality
18.9.3.By Deployment
18.9.4.By Product Type
18.9.5.By Vendor Type
18.9.6.By Application
18.9.7.By End User
19.Competitive Benchmarking
19.1.Brand Benchmarking
19.2.Market Share Analysis, 2023
19.3.Global Presence and Growth Strategies
19.3.1.Mergers and Acquisitions
19.3.2.Product Launches
19.3.3.Investments Trends
19.3.4.R&D Initiatives
20.Player Profiles
20.1.Agfa Healthcare NV
20.1.1.Company Details
20.1.2.Company Overview
20.1.3.Product Offerings
20.1.4.Key Developments
20.1.5.Financial Analysis
20.1.6.SWOT Analysis
20.1.7.Business Strategies
20.2.Dell Technologies Inc.
20.2.1.Company Details
20.2.2.Company Overview
20.2.3.Product Offerings
20.2.4.Key Developments
20.2.5.Financial Analysis
20.2.6.SWOT Analysis
20.2.7.Business Strategies
20.3.FUJIFILM Holdings Corporation
20.3.1.Company Details
20.3.2.Company Overview
20.3.3.Product Offerings
20.3.4.Key Developments
20.3.5.Financial Analysis
20.3.6.SWOT Analysis
20.3.7.Business Strategies
20.4.GE Healthcare
20.4.1.Company Details
20.4.2.Company Overview
20.4.3.Product Offerings
20.4.4.Key Developments
20.4.5.Financial Analysis
20.4.6.SWOT Analysis
20.4.7.Business Strategies
20.5.IBM Corporation
20.5.1.Company Details
20.5.2.Company Overview
20.5.3.Product Offerings
20.5.4.Key Developments
20.5.5.Financial Analysis
20.5.6.SWOT Analysis
20.5.7.Business Strategies
20.6.Koninklijke Philips NV
20.6.1.Company Details
20.6.2.Company Overview
20.6.3.Product Offerings
20.6.4.Key Developments
20.6.5.Financial Analysis
20.6.6.SWOT Analysis
20.6.7.Business Strategies
20.7.Lexmark International Inc.
20.7.1.Company Details
20.7.2.Company Overview
20.7.3.Product Offerings
20.7.4.Key Developments
20.7.5.Financial Analysis
20.7.6.SWOT Analysis
20.7.7.Business Strategies
20.8.McKesson Corporation
20.8.1.Company Details
20.8.2.Company Overview
20.8.3.Product Offerings
20.8.4.Key Developments
20.8.5.Financial Analysis
20.8.6.SWOT Analysis
20.8.7.Business Strategies
20.9.Novarad Corporation
20.9.1.Company Details
20.9.2.Company Overview
20.9.3.Product Offerings
20.9.4.Key Developments
20.9.5.Financial Analysis
20.9.6.SWOT Analysis
20.9.7.Business Strategies
20.10.Siemens Healthineers AG
20.10.1.Company Details
20.10.2.Company Overview
20.10.3.Product Offerings
20.10.4.Key Developments
20.10.5.Financial Analysis
20.10.6.SWOT Analysis
20.10.7.Business Strategies
20.11.Other Market Participants
21.Key Findings

.

**Exclusive for Multi-User and Enterprise User.

Global Vendor Neutral Archive (VNA) & PACS Market

By Modality

  • CT
  • Mammography
  • MRI
  • Ultrasound
  • X-Rays
  • PET

By Deployment

  • On-Premise
  • Cloud-Based
  • Hybrid Model

By Product Type

  • VNA
    • Department VNA
    • Multi-Department VNA
    • Multi-Site VNA
  • PACS
    • Department PACS
    • Multi-Department PACS
    • Multi-Site PACS

By Vendor Type

  • Independent Vendor
  • Third-party Vendor

By Application

  • Cardiology
  • Orthopedic
  • Oncology
  • Neurology
  • Obstetrics and Gynecology
  • Others

By End User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

The Niche Research approach encompasses both primary and secondary research methods to provide comprehensive insights. While primary research is the cornerstone of our studies, we also incorporate secondary research sources such as company annual reports, premium industry databases, press releases, industry journals, and white papers.

Within our primary research, we actively engage with various industry stakeholders, conducting paid interviews and surveys. Our meticulous analysis extends to every market participant in major countries, allowing us to thoroughly examine their portfolios, calculate market shares, and segment revenues.

Our data collection primarily focuses on individual countries within our research scope, enabling us to estimate regional market sizes. Typically, we employ a bottom-up approach, meticulously tracking trends in different countries. We analyze growth drivers, constraints, technological innovations, and opportunities for each country, ultimately arriving at regional figures.Our process begins by examining the growth prospects of each country. Building upon these insights, we project growth and trends for the entire region. Finally, we utilize our proprietary model to refine estimations and forecasts.

Our data validation standards are integral to ensuring the reliability and accuracy of our research findings. Here’s a breakdown of our data validation processes and the stakeholders we engage with during our primary research:

  • Supply Side Analysis: We initiate a supply side analysis by directly contacting market participants, through telephonic interviews and questionnaires containing both open-ended and close-ended questions. We gather information on their portfolios, segment revenues, developments, and growth strategies.
  • Demand Side Analysis: To gain insights into adoption trends and consumer preferences, we reach out to target customers and users (non-vendors). This information forms a vital part of the qualitative analysis section of our reports, covering market dynamics, adoption trends, consumer behavior, spending patterns, and other related aspects.
  • Consultant Insights: We tap into the expertise of our partner consultants from around the world to obtain their unique viewpoints and perspectives. Their insights contribute to a well-rounded understanding of the markets under investigation.
  • In-House Validation: To ensure data accuracy and reliability, we conduct cross-validation of data points and information through our in-house team of consultants and utilize advanced data modeling tools for thorough verification.

The forecasts we provide are based on a comprehensive assessment of various factors, including:

  • Market Trends and Past Performance (Last Five Years): We accurately analyze market trends and performance data from preceding five years to identify historical patterns and understand the market’s evolution.
  • Historical Performance and Growth of Market Participants: We assess the historical performance and growth trajectories of key market participants. This analysis provides insights into the competitive landscape and individual company strategies.
  • Market Determinants Impact Analysis (Next Eight Years): We conduct a rigorous analysis of the factors that are projected to influence the market over the next eight years. This includes assessing both internal and external determinants that can shape market dynamics.
  • Drivers and Challenges for the Forecast Period:Identify the factors expected to drive market growth during the forecast period, as well as the challenges that the industry may face. This analysis aids in deriving an accurate growth rate projection.
  • New Acquisitions, Collaborations, or Partnerships: We keep a close watch on any new acquisitions, collaborations, or partnerships within the industry. These developments can have a significant impact on market dynamics and competitiveness.
  • Macro and Micro Factors Analysis:A thorough examination of both macro-level factors (e.g., economic trends, regulatory changes) and micro-level factors (e.g., technological advancements, consumer preferences) that may influence the market during the forecast period.
  • End-User Sentiment Analysis: To understand the market from the end-user perspective, we conduct sentiment analysis. This involves assessing the sentiment, preferences, and feedback of the end-users, which can provide valuable insights into market trends.
  • Perspective of Primary Participants: Insights gathered directly from primary research participants play a crucial role in shaping our forecasts. Their perspectives and experiences provide valuable qualitative data.
  • Year-on-Year Growth Trend: We utilize a year-on-year growth trend based on historical market growth and expected future trends. This helps in formulating our growth projections, aligning them with the market’s historical performance.

Research process adopted by TNR involves multiple stages, including data collection, validation, quality checks, and presentation. It’s crucial that the data and information we provide add value to your existing market understanding and expertise. We have also established partnerships with business consulting, research, and survey organizations across regions and globally to collaborate on regional analysis and data validation, ensuring the highest level of accuracy and reliability in our reports.

 

 

Procure Comprehensive Study of

Global Vendor Neutral Archive (VNA) & PACS Market

Online Only

  • Online Access
  • Read Only File
  • Validity 3 Months
  • Print, Copy, Paste & Download
  • PPT, Excel
  • Cost-Free Report in the Next Update
$3300
Buy Now

Single User

  • Access to One User on One System
  • Read Only File
  • Validity 6 Months
  • Limited Print,Copy, Paste
  • PPT, Excel
  • Cost-Free Report in the Next Update
$4200
Buy Now

Multi User

  • Access to Fiver Users
  • PDF File
  • Validity 1 Year
  • Upto FivePrints
  • Cost-Free Report in the Next Update
  • PPT, Excel
$6000
Buy Now

Enterprise User

  • Access to Unlimited Users
  • PDF, PPT, Excel
  • Unlimited Validity, Prints&Downloads
  • 1 Hour Cost-Free & Dedicated Analyst Support
  • 10% Cost-Free Customization
  • Cost-Free Report Update Twice in a Year
  • Recommendations for Business Strategies
  • Authorization to Quote TNR, The Niche Research
$7300
Buy Now

Library Access

  • Online Access to Content Publications
  • Access Player Profiles Online
  • Get Immediate Access to Newly Added Content
  • Acquire 12 PDF Downloads
  • Acquire 5 Excel Data Sets
  • Gain Access to 290+ PDFs of Company Profiles
  • Round-the-clock Email and Phone Assistance
  • Dashboard Usage and Trends
  • Renewal & Upgrade Assistance
  • Assessing Customization Options and Alerts for New Reports
$10788
Buy Now
*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Why TNR The Niche Research?

  • Unwavering Commitment to Excellence

  • Veteran Team of Researchers

  • Accurate and Timely Insights

  • Ethical Practices and Customized Service

  • Uninterrupted Availability Around the Clock

Scroll to Top